Published in J Neuroimmunol on October 15, 2008
Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol (2008) 1.08
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res (2009) 1.01
An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci (2014) 0.91
Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment. J Neurosci (2015) 0.87
The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis. J Neuroinflammation (2012) 0.86
Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic. J Neuroinflammation (2015) 0.83
MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses. PLoS One (2016) 0.78
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature (1992) 7.20
A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2003) 5.77
CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med (2000) 3.09
Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev (1995) 2.92
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) (1997) 2.55
An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol (1995) 2.52
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol (2006) 2.38
Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol (1995) 2.13
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology (2005) 2.06
MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol (1998) 1.96
The effects of macrophage depletion on the clinical and pathologic expression of experimental allergic encephalomyelitis. J Immunol (1981) 1.79
Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol (1998) 1.72
Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol (1998) 1.63
IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest (2003) 1.50
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Production and function of monocyte chemoattractant protein-1 and other beta-chemokines in murine glial cells. J Neuroimmunol (1995) 1.27
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett (2006) 1.18
Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol (2007) 1.17
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc Natl Acad Sci U S A (1999) 1.11
Differential tumor necrosis factor alpha expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med (1991) 1.10
Flow cytometric and functional analyses of central nervous system-infiltrating cells in SJL/J mice with Theiler's virus-induced demyelinating disease. Evidence for a CD4+ T cell-mediated pathology. J Immunol (1996) 1.10
Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. J Neurochem (2005) 1.05
Macrophages regulate induction of delayed-type hypersensitivity and experimental allergic encephalomyelitis in SJL mice. Eur J Immunol (1995) 1.00
Optimizing the detection of cell surface antigens on elicited or activated mouse peritoneal macrophages. Cytometry (1994) 0.80
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
Heparin binding nanostructures to promote growth of blood vessels. Nano Lett (2006) 2.65
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment. Proc Natl Acad Sci U S A (2003) 1.62
Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int Rev Neurobiol (2007) 1.59
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation (2008) 1.57
Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res (2009) 1.53
University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res (2012) 1.52
Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg Med Chem (2009) 1.49
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging (2004) 1.42
Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol (2013) 1.41
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis (2005) 1.39
Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia (2007) 1.32
Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. Neurosci Res (2007) 1.27
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ). J Neuroinflammation (2011) 1.25
A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci (2004) 1.24
Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia (2006) 1.22
MFG-E8 regulates microglial phagocytosis of apoptotic neurons. J Neuroimmune Pharmacol (2008) 1.20
Non-muscle myosin light chain kinase isoform is a viable molecular target in acute inflammatory lung injury. Am J Respir Cell Mol Biol (2010) 1.19
Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia (2004) 1.19
Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging (2004) 1.18
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett (2006) 1.18
Neuroinflammation: a potential therapeutic target. Expert Opin Ther Targets (2005) 1.16
S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem (2005) 1.13
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. Bioorg Med Chem Lett (2003) 1.11
ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci (2004) 1.10
The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. Aging Dis (2010) 1.09
The p38α MAPK regulates microglial responsiveness to diffuse traumatic brain injury. J Neurosci (2013) 1.08
Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem (2013) 1.07
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation (2008) 1.07
Association between male gender and cortical Lewy body pathology in large autopsy series. J Neurol (2010) 1.06
A role for long chain myosin light chain kinase (MLCK-210) in microvascular hyperpermeability during severe burns. Shock (2007) 1.05
Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis (2011) 1.03
Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα. Mol Neurodegener (2011) 1.03
Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci (2004) 1.02
Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis (2012) 1.01
Enhanced microglial activation and proinflammatory cytokine upregulation are linked to increased susceptibility to seizures and neurologic injury in a 'two-hit' seizure model. Brain Res (2009) 1.01
Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation (2005) 1.01
A calmodulin-regulated protein kinase linked to neuron survival is a substrate for the calmodulin-regulated death-associated protein kinase. Biochemistry (2004) 1.00
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorg Med Chem (2010) 0.99
Minozac treatment prevents increased seizure susceptibility in a mouse "two-hit" model of closed skull traumatic brain injury and electroconvulsive shock-induced seizures. J Neurotrauma (2010) 0.98
Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS One (2013) 0.97
Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis (2013) 0.97
Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction. PLoS One (2013) 0.96
APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem (2015) 0.96
DAPK catalytic activity in the hippocampus increases during the recovery phase in an animal model of brain hypoxic-ischemic injury. Biochim Biophys Acta (2002) 0.96
MLCK210 gene knockout or kinase inhibition preserves lung function following endotoxin-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol (2007) 0.96
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model. Curr Alzheimer Res (2005) 0.95
Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener (2014) 0.93
Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem (2002) 0.92
Myosin light chain kinase (210 kDa) is a potential cytoskeleton integrator through its unique N-terminal domain. Exp Cell Res (2004) 0.92
Increased susceptibility of S100B transgenic mice to perinatal hypoxia-ischemia. Ann Neurol (2004) 0.92
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. Neurobiol Dis (2011) 0.91
A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells. Transl Stroke Res (2011) 0.91
Nonmuscle myosin light chain kinase regulates murine asthmatic inflammation. Am J Respir Cell Mol Biol (2014) 0.91
Death-associated protein kinase phosphorylates mammalian ribosomal protein S6 and reduces protein synthesis. Biochemistry (2006) 0.90
Death-associated protein kinase as a potential therapeutic target. Expert Opin Ther Targets (2002) 0.90
"End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis (2011) 0.90
Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo. J Interferon Cytokine Res (2012) 0.89
Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement (2013) 0.89
Deletion of MLCK210 induces subtle changes in vascular reactivity but does not affect cardiac function. Am J Physiol Heart Circ Physiol (2005) 0.88
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res (2006) 0.88
Structural insight into nucleotide recognition by human death-associated protein kinase. Acta Crystallogr D Biol Crystallogr (2009) 0.88
Effect of potential amine prodrugs of selective neuronal nitric oxide synthase inhibitors on blood-brain barrier penetration. Bioorg Med Chem (2009) 0.87
Protection against endotoxic shock as a consequence of reduced nitrosative stress in MLCK210-null mice. Am J Pathol (2007) 0.87